Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Seamless transition from preclinical to first-in-human trials with EUDRACAP platform technology
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Increased capability to produce medicines for challenging diseases including cancer
Lokavant provides clinical trial intelligence
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Commenced operations in flood-affected Himachal Pradesh
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Subscribe To Our Newsletter & Stay Updated
